479 related articles for article (PubMed ID: 19620247)
21. The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.
Derwich A; Sykutera M; Bromińska B; Rubiś B; Ruchała M; Sawicka-Gutaj N
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446128
[TBL] [Abstract][Full Text] [Related]
22. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
Fritsche-Guenther R; Witzel F; Kempa S; Brummer T; Sers C; Blüthgen N
Oncotarget; 2016 Feb; 7(7):7960-9. PubMed ID: 26799289
[TBL] [Abstract][Full Text] [Related]
23. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
Su CC
Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
[TBL] [Abstract][Full Text] [Related]
24. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
[TBL] [Abstract][Full Text] [Related]
25. Ras transformation of RIE-1 cells activates cap-independent translation of ornithine decarboxylase: regulation by the Raf/MEK/ERK and phosphatidylinositol 3-kinase pathways.
Origanti S; Shantz LM
Cancer Res; 2007 May; 67(10):4834-42. PubMed ID: 17510413
[TBL] [Abstract][Full Text] [Related]
26. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
27. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals.
von Gise A; Lorenz P; Wellbrock C; Hemmings B; Berberich-Siebelt F; Rapp UR; Troppmair J
Mol Cell Biol; 2001 Apr; 21(7):2324-36. PubMed ID: 11259582
[TBL] [Abstract][Full Text] [Related]
28. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway.
Wang Q; Zhang X; Song X; Zhang L
Arch Oral Biol; 2018 Dec; 96():74-79. PubMed ID: 30195142
[TBL] [Abstract][Full Text] [Related]
30. Regulation of the RAP1/RAF-1/extracellularly regulated kinase-1/2 cascade and prolactin release by the phosphoinositide 3-kinase/AKT pathway in pituitary cells.
Romano D; Pertuit M; Rasolonjanahary R; Barnier JV; Magalon K; Enjalbert A; Gerard C
Endocrinology; 2006 Dec; 147(12):6036-45. PubMed ID: 16935846
[TBL] [Abstract][Full Text] [Related]
31. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
32. Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src.
Aziz N; Cherwinski H; McMahon M
Mol Cell Biol; 1999 Feb; 19(2):1101-15. PubMed ID: 9891045
[TBL] [Abstract][Full Text] [Related]
33. PI3K pathway is involved in ERK signaling cascade activation by histamine H2R agonist in HEK293T cells.
Alonso N; Diaz Nebreda A; Monczor F; Gutkind JS; Davio C; Fernandez N; Shayo C
Biochim Biophys Acta; 2016 Sep; 1860(9):1998-2007. PubMed ID: 27316323
[TBL] [Abstract][Full Text] [Related]
34. Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome.
Lakiotaki E; Levidou G; Angelopoulou MK; Adamopoulos C; Pangalis G; Rassidakis G; Vassilakopoulos T; Gainaru G; Flevari P; Sachanas S; Saetta AA; Sepsa A; Moschogiannis M; Kalpadakis C; Tsesmetzis N; Milionis V; Chatziandreou I; Thymara I; Panayiotidis P; Dimopoulou M; Plata E; Konstantopoulos K; Patsouris E; Piperi C; Korkolopoulou P
Sci Rep; 2016 Feb; 6():21252. PubMed ID: 26893254
[TBL] [Abstract][Full Text] [Related]
35. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.
Prasad A; Park IW; Allen H; Zhang X; Reddy MV; Boominathan R; Reddy EP; Groopman JE
Oncogene; 2009 Mar; 28(12):1518-28. PubMed ID: 19198627
[TBL] [Abstract][Full Text] [Related]
36. Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt.
Link W; Rosado A; Fominaya J; Thomas JE; Carnero A
J Cell Biochem; 2005 Aug; 95(5):979-89. PubMed ID: 15838873
[TBL] [Abstract][Full Text] [Related]
37. Targeted RNA interference of phosphatidylinositol 3-kinase p110-beta induces apoptosis and proliferation arrest in endometrial carcinoma cells.
An HJ; Cho NH; Yang HS; Kwak KB; Kim NK; Oh DY; Lee SW; Kim HO; Koh JJ
J Pathol; 2007 Jun; 212(2):161-9. PubMed ID: 17427168
[TBL] [Abstract][Full Text] [Related]
38. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.
Perrone F; Da Riva L; Orsenigo M; Losa M; Jocollè G; Millefanti C; Pastore E; Gronchi A; Pierotti MA; Pilotti S
Neuro Oncol; 2009 Dec; 11(6):725-36. PubMed ID: 19246520
[TBL] [Abstract][Full Text] [Related]
39. Overexpression and overactivation of Akt in thyroid carcinoma.
Ringel MD; Hayre N; Saito J; Saunier B; Schuppert F; Burch H; Bernet V; Burman KD; Kohn LD; Saji M
Cancer Res; 2001 Aug; 61(16):6105-11. PubMed ID: 11507060
[TBL] [Abstract][Full Text] [Related]
40. Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death.
Hu P; Han Z; Couvillon AD; Exton JH
J Biol Chem; 2004 Nov; 279(47):49420-9. PubMed ID: 15339911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
